Dulaglutide
Aliases: Trulicity
Last verified: 2026-09-23
The short version
A weekly GLP-1 agonist (Fc fusion) — approved for type 2 diabetes with proven CV protection (REWIND).
Identity & type
- Molecular type
- analog
- Origin
- A weekly GLP-1 agonist (Fc fusion) — approved for type 2 diabetes with proven CV protection (REWIND).
Mechanism of action
GLP-1R agonism; long half-life via IgG4-Fc fusion.
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. 0.75–4.5 mg SC weekly.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
0.75–4.5 mg SC weekly. Trulicity: reliable weekly glycemic control with modest weight effect; excellent tolerability and CV benefit in diabetics.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Trulicity: reliable weekly glycemic control with modest weight effect; excellent tolerability and CV benefit in diabetics.
Protocol — official vs community
Official / label
Trulicity, for type 2 diabetes: 0.75 mg SC once weekly as the starting dose; may increase to 1.5 mg, 3 mg or 4.5 mg once weekly for additional glycemic control.
- 01Start: 0.75 mg once weekly
- 02If needed: increase to 1.5 mg once weekly (may start directly at 1.5 mg)
- 03If needed: 3 mg once weekly
- 04If needed: 4.5 mg once weekly (maximum)
- 05Dose increases at intervals of ≥4 weeks
Duration: Chronic. CV benefit (REWIND: ~12% MACE reduction) accrues over years.
Flat, prefilled pen — no reconstitution. Discontinuation reverses both glycemic and weight effects. Off-label for obesity mirrors the semaglutide pattern but at weaker effect sizes.
Community (anecdotal)
Mirrors the label: 0.75–4.5 mg SC weekly. Gray-market diversion is less common than for semaglutide/tirzepatide because effect on weight is comparatively modest.
- Cycle:
- Continuous — not cycled.
- Break:
- None by design; regain follows discontinuation.
In community discussions Trulicity is mostly a fallback when preferred GLP-1s are unavailable or unaffordable.
Human evidence
REWIND: −12% MACE, including primary prevention.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- GI side effects; MTC warning.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Real-world data outside controlled trials